Autonomix (NASDAQ: AMIX) to Present at the Benzinga Virtual Healthcare Summit 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Live webcast presentation on Wednesday, March 20th at 11:50 AM ET

THE WOODLANDS, TX, March 20, 2024 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, announced today that Lori Bisson, Chief Executive Officer of Autonomix will present at the Benzinga Virtual Healthcare Summit 2024 on Wednesday, March 20, 2024 at 11:50 AM ET.

Benzinga’s Virtual Healthcare Summit is a virtual event where the brightest minds in healthcare, influential companies, analysts, and thought leaders converge to shape the future of health. Join the event for a dynamic exploration of the healthcare and biotech landscape, covering topics including AI, telemedicine, oncology, medical devices, healthcare M&A activity, and the latest start-ups.

To register for the event and access the Autonomix presentation, please visit the Benzinga Virtual Healthcare Summit 2024 event website.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Investor and Media Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
autonomix@jtcir.com

Staff

Recent Posts

Tariff Uncertainty Disrupts Healthcare Operations: New Diagnostic Survey Highlights Staffing Changes, Delayed Purchases, and Supply Chain Strain

ARLINGTON, Va., June 26, 2025 /PRNewswire/ -- A new survey of 195 diagnostic imaging and…

37 minutes ago

Ultima Genomics Selected to Support the World’s Largest Proteomics Studies to Date Led by Regeneron Genetics Center

FREMONT, Calif., June 26, 2025 /PRNewswire/ -- Ultima Genomics, a developer of an innovative new…

37 minutes ago

Therap Enhances Secure Document Signing with Added ‘Order’ Module Search Option in Reference Module Dropdown

TORRINGTON, Conn., June 26, 2025 /PRNewswire/ -- Therap Services, the leading provider of HIPAA-compliant electronic documentation…

37 minutes ago

Los Angeles Center for Ear, Nose, Throat and Allergy Introduces Clarity Technologies’ New Audiology Video Library

Cutting-edge tool aims to enhance patient education and experience while improving operational efficiency LOS ANGELES,…

37 minutes ago

MyndTec Announces Results of Annual General and Special Meeting of Shareholders

Mississauga, Ontario--(Newsfile Corp. - June 26, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the…

2 hours ago

Canadian Institute of Actuaries Announces Alicia Rollo as New Executive Director

Ottawa, Ontario--(Newsfile Corp. - June 26, 2025) - As the Canadian Institute of Actuaries (CIA)…

7 hours ago